Cargando…
Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease
Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia. Importantly, evidence suggests that these drugs may also be neuroprotective against glutamate excitotoxicity, implicated in the pathogenesis...
Autores principales: | Chan, Hugh, Paur, Helen, Vernon, Anthony C., Zabarsky, Virginia, Datla, Krishna P., Croucher, Martin J., Dexter, David T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951138/ https://www.ncbi.nlm.nih.gov/pubmed/20948891 http://dx.doi.org/10.4061/2010/190450 |
Ejemplares similares
-
mGluR5, CB1 and neuroprotection
por: Carvalho, Toniana G., et al.
Publicado: (2016) -
Orchestrated activation of mGluR5 and CB(1) promotes neuroprotection
por: Batista, Edleusa M. L., et al.
Publicado: (2016) -
Group I mGluRs in Therapy and Diagnosis of Parkinson’s Disease: Focus on mGluR5 Subtype
por: Azam, Shofiul, et al.
Publicado: (2022) -
mGluR-dependent plasticity in rodent models of Alzheimer’s disease
por: Valdivia, Gonzalo, et al.
Publicado: (2023) -
The orthosteric agonist 2-chloro-5-hydroxyphenylglycine activates mGluR5 and mGluR1 with similar efficacy and potency
por: Kammermeier, Paul J
Publicado: (2012)